Updates are available Correction dated 2021-07-23
Click to view Correction: https://doi.org/10.1007/s40262-021-01060-8
-
Authors
James, Angela Joubert
Smith, Catherine C.
Litzow, Mark
Perl, Alexander E.
Altman, Jessica K.
Shepard, Dale
Kadokura, Takeshi
Souda, Kinya
Patton, Melanie
Lu, Zheng
Liu, Chaofeng
Moy, Selina
Levis, Mark J.
Bahceci, Erkut
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02014558 at ClinicalTrials.govnct02456883 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
https://doi.org/10.1007/s40262-020-00888-w
nct02571816 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
https://doi.org/10.1007/s40262-020-00888-w
Documents that mention this clinical trial
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
https://doi.org/10.1007/s40262-020-00888-w
-
Funding
Funding for this research was provided by:
Astellas Pharma, Inc.
- License Information
-
More Information
Article History
First Online: 18 April 2020
Change Date: 23 July 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40262-021-01060-8
Compliance with Ethical Standards
:
: Angela Joubert James, Melanie Patton, Chaofeng Liu, Selina Moy, and Erkut Bahceci are employees of Astellas Pharma, US Inc. Zheng Lu was an employee of Astellas Pharma US, Inc. during the time of the study and development of the manuscript. Takeshi Kadokura and Kinya Souda are employees of Astellas Pharma, Inc. Catherine C. Smith received research grants from Astellas Pharma US, Inc. Mark Litzow has no conflicts of interest that are directly relevant to the content of this article. Alexander E. Perl has received funding, honoraria, or travel reimbursement from Astellas, Daiichi-Sankyo, Arog, Novartis, Pfizer, Actinium Pharmaceuticals, Jazz Pharmaceuticals, Takeda, AbbVie, NewLink Genetics, Asana Biosciences, and Seattle Genetics. Jessica K. Altman has received funding, honoraria, or travel reimbursement from AbbVie, Agios, Ariad, Astellas, Bayer, BioSight, BMS, Boeringer Ingelheim, Cancer Expert Now, Celator, Celgene, Daiichi Sankyo, Epizyme, France Foundation, FujiFilm, Genentech, Glycomimetics, GSK, Incyte, Janssen Pharmaceuticals, Novartis, PeerView, Pfizer, prIME Oncology, Syros, and Theradex. Dale Shepard has received funding, honoraria, or travel reimbursement from Celgene, Sanofi, AstraZeneca, Ipsen, Amgen, Genentech, Eli Lilly, Bayer, Leap, Alkermes, Aduro, Halozyme, Ignyta, BMS, Pfizer, Kinex, and Corvus. Mark J. Levis has received funding or personal fees from Astellas, Novartis, Daiichi-Sankyo, and FujiFilm.
: For investigations involving human subjects, informed consent was obtained from the participants involved.
: Researchers may request access to anonymized participant-level data, trial-level data, and protocols from Astellas-sponsored clinical trials at ExternalRef removed. For the Astellas criteria on data sharing, see ExternalRef removed.
: The research was conducted within all the appropriate ethical and legal guidelines.
